Clinical Study
Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines
Table 3
Multivariate analysis of PC risk and HGPCa risk according to the treatment with statins and aspirin respect no treatment.
| Treatment | PCa detection* | value | HGPCa detection* | value |
| Age (years) | 1.066 (1.049–1.084) | 0.001 | 1.100 (1.071–1.130) | 0.001 | BMI (Kg/m2) | 1.018 (0.001–1.047) | 0.189 | 0.989 (0.948–1.032) | 0.616 | PSA (ng/mL) | 1.024 (1.008–1.041) | 0.004 | 1.038 (1.027–1.049) | 0.001 | DRE (positive versus negative) | 1.219 (1.028–1.428) | 0.001 | 1.266 (0.879–1.822) | 0.205 | Statin (yes versus no) | 0.910 (0.728–11.137) | 0.430 | 1.092 (0.725–1.646) | 0.637 | Aspirin (yes versus no) | 1.150 (0.824–1.604) | 0.439 | 1.835 (1.068–3.155) | 0.028 | Statins + aspirin (yes versus no) | 0.616 (0.467–0.812) | <0.001 | 3.059 (1.894–4.939) | <0.001 | Time on statins (months) | 0.998 (0.955–1.000) | 0.063 | 1.005 (1.000–1.010) | 0.034 | Time on aspirins (months) | 0.984 (0.979–0.990) | <0.001 | 1.033 (1.020–1.047) | <0.001 |
|
|
BMI: body mass index, PSA: prostate specific antigen, and DRE: digital rectal examination. Values expressed as odds ratio (95% confidence interval).
|